Chmp Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb’s Opdivo® (Nivolumab) in Combination With Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients With Unresectable or Metastatic Urothelial Carcinoma
Chmp 採納正面意見，建議批准百時美施貴寶的 Opdivo®（Nivolumab）與順鉑和吉西他濱聯合用於不可切除或轉移性尿路上皮癌成年患者的一線治療